Advanced Solid Tumors with AKT1 E17K Mutation research hub

AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation

This study is testing a new medicine, ALTA2618, for people with advanced cancers. It's for those whose cancer has a specific change called an AKT1 E17K mutation. This is a very early study to see if the medicine is safe and how it works.